More than 1050 clinical trials are registered at FDA.gov that explore multipotent
mesenchymal stromal cells (MSCs) for nearly every clinical application imaginable, including …

Despite the development of new glioma therapies that allow for tumor-targeted in situ delivery
of cytotoxic drugs, tumor resistance to apoptosis remains a key impediment to effective …

Mesenchymal stem/stromal cells (MSCs) are multipotent cells that are emerging as the most
promising means of allogeneic cell therapy. MSCs have inherent immunomodulatory …

The poor prognosis of patients with aggressive and invasive cancers combined with toxic
effects and short half-life of currently available treatments necessitate development of more …

The recent revelation that the gut microbiome, home to approximately 100 trillion
microorganisms, is implicated in the development of both health and disease has spurred an …

Glioblastoma (GBM) is a highly aggressive brain cancer characterized by local invasion and
angiogenic recruitment, yet metastatic dissemination is extremely rare. Here, we adapted a …

The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) …

Therapeutically engineered stem cells have shown promise for glioblastoma multiforme (GBM)
therapy; however, key preclinical studies are urgently needed for their clinical translation. …

The ability to noninvasively track the migration, engraftment, and proliferation of neural
progenitor cells (NPCs) has significant clinical and research implications. The purpose of our …

β-Galactosidase (β-gal) has been widely used as a transgene reporter enzyme, and several
substrates are available for its in vitro detection. The ability to image β-gal expression in …